SA520411881B1 - صياغات إطلاق مديد لتطبيقات داخل المفصل - Google Patents

صياغات إطلاق مديد لتطبيقات داخل المفصل

Info

Publication number
SA520411881B1
SA520411881B1 SA520411881A SA520411881A SA520411881B1 SA 520411881 B1 SA520411881 B1 SA 520411881B1 SA 520411881 A SA520411881 A SA 520411881A SA 520411881 A SA520411881 A SA 520411881A SA 520411881 B1 SA520411881 B1 SA 520411881B1
Authority
SA
Saudi Arabia
Prior art keywords
intra
extended release
release formulations
oxabicyclo
dichlorophenyl
Prior art date
Application number
SA520411881A
Other languages
Arabic (ar)
English (en)
Inventor
فيش أندرياس
أولريك ريبسيل بيرند
كاستانولي كارلو
لورشيدر ماثيلد
لاكسمان نيهاركار مانجالي
Original Assignee
نوفارتيس إيه جي
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by نوفارتيس إيه جي filed Critical نوفارتيس إيه جي
Publication of SA520411881B1 publication Critical patent/SA520411881B1/ar

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/443Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4465Non condensed piperidines, e.g. piperocaine only substituted in position 4
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SA520411881A 2017-11-10 2020-04-30 صياغات إطلاق مديد لتطبيقات داخل المفصل SA520411881B1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762584589P 2017-11-10 2017-11-10
US201862743864P 2018-10-10 2018-10-10

Publications (1)

Publication Number Publication Date
SA520411881B1 true SA520411881B1 (ar) 2024-01-04

Family

ID=64402238

Family Applications (1)

Application Number Title Priority Date Filing Date
SA520411881A SA520411881B1 (ar) 2017-11-10 2020-04-30 صياغات إطلاق مديد لتطبيقات داخل المفصل

Country Status (23)

Country Link
US (1) US20210177824A1 (https=)
EP (1) EP3706710B1 (https=)
JP (1) JP7284750B2 (https=)
KR (1) KR20200087138A (https=)
CN (1) CN111278410A (https=)
AU (1) AU2018364685B2 (https=)
CA (1) CA3075722A1 (https=)
CL (1) CL2020001156A1 (https=)
DK (1) DK3706710T3 (https=)
ES (1) ES2981903T3 (https=)
FI (1) FI3706710T3 (https=)
HR (1) HRP20240808T1 (https=)
HU (1) HUE066971T2 (https=)
IL (2) IL305541A (https=)
LT (1) LT3706710T (https=)
MX (2) MX2020004477A (https=)
PL (1) PL3706710T3 (https=)
PT (1) PT3706710T (https=)
RS (1) RS65659B1 (https=)
SA (1) SA520411881B1 (https=)
SI (1) SI3706710T1 (https=)
TW (2) TWI813597B (https=)
WO (1) WO2019092637A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113015735B (zh) * 2018-12-06 2024-06-21 诺华股份有限公司 用于诱导软骨发生以治疗关节损害的5-羟基-7-氧杂双环[2.2.1]庚烷-2-甲酰胺衍生物
US20230414601A1 (en) * 2020-11-30 2023-12-28 Lg Chem, Ltd. Injectable composition containing caspase inhibitor, and preparation method therefor
KR20240133027A (ko) 2023-02-28 2024-09-04 주식회사 포스테라헬스사이언스 올리고펩타이드를 포함하는 서방형 입자 및 이의 제조 방법

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI527590B (zh) * 2011-06-17 2016-04-01 艾瑞斯貿易公司 Fgf-18之凍乾調配物
DK3143026T3 (da) * 2014-05-13 2024-09-30 Novartis Ag Forbindelser og sammensætninger til induktion af chondrogenese

Also Published As

Publication number Publication date
PT3706710T (pt) 2024-06-27
TW201922245A (zh) 2019-06-16
PL3706710T3 (pl) 2024-08-05
JP7284750B2 (ja) 2023-05-31
HRP20240808T1 (hr) 2024-09-27
US20210177824A1 (en) 2021-06-17
IL274149B2 (en) 2024-02-01
AU2018364685B2 (en) 2021-05-20
IL305541A (en) 2023-10-01
RU2020115439A (ru) 2021-12-10
FI3706710T3 (fi) 2024-07-08
MX2020004477A (es) 2020-08-03
EP3706710A1 (en) 2020-09-16
EP3706710B1 (en) 2024-04-10
IL274149A (en) 2020-06-30
DK3706710T3 (da) 2024-07-08
LT3706710T (lt) 2024-07-10
TWI813597B (zh) 2023-09-01
AU2018364685A1 (en) 2020-03-26
TW202400164A (zh) 2024-01-01
IL274149B1 (en) 2023-10-01
CL2020001156A1 (es) 2020-10-30
HUE066971T2 (hu) 2024-09-28
RU2020115439A3 (https=) 2021-12-10
SI3706710T1 (sl) 2024-08-30
CA3075722A1 (en) 2019-05-16
KR20200087138A (ko) 2020-07-20
WO2019092637A1 (en) 2019-05-16
CN111278410A (zh) 2020-06-12
MX2023007036A (es) 2023-06-28
RS65659B1 (sr) 2024-07-31
BR112020008806A2 (pt) 2020-10-20
ES2981903T3 (es) 2024-10-14
JP2021502337A (ja) 2021-01-28

Similar Documents

Publication Publication Date Title
EP4491199A3 (en) Gadolinium bearing pcta-based contrast agents
MX2022003102A (es) Degradadores bifuncionales de brd9 y sus metodos de uso.
WO2017205536A3 (en) Heterocyclic inhibitors of cbp/ep300 and their use in the treatment of cancer
PH12018501956A1 (en) 3-desoxy derivative and pharmaceutical compositions thereof
EP4420679A3 (en) Lipids and lipid nanoparticle formulations for delivery of nucleic acids
MX2010006799A (es) Benzofuropirimidinonas como inhibidores de la proteina cinasa.
MX418519B (es) Inhibidores selectivos de jak1
ZA202004023B (en) 1,2,4-oxadiazole derivatives as histone deacetylase 6 inhibitors
AU2016343803A8 (en) Novel lipids and lipid nanoparticle formulations for delivery of nucleic acids
WO2017132432A8 (en) Benzimidazole derivatives as modulators of ror-gamma
MX2016010056A (es) 6-heteroariloxi o 6-ariloxi-quinolina-2-carboxamidas y metodos de uso.
WO2018121559A8 (zh) 甘露糖醛二酸的组合物
MX379459B (es) Inhibidores de bromodominios.
MX2021000093A (es) Antagonistas del receptor de tipo toll 7/8 (tlr7/8) y usos de los mismos.
EA201891267A1 (ru) Фармацевтическая композиция, содержащая действенный ингибитор urat1
MX2023007036A (es) Formulaciones de liberacion prolongada para aplicaciones intra-articulares.
PH12022550338A1 (en) 2-hydroxycycloalkane-1-carbamoyl derivatives
MX2020012978A (es) Sales de sepiapterina farmacéuticamente aceptables.
JOP20180071B1 (ar) استخدام مشتقات أمينو ألكيل بنزوثيازبين
WO2018209363A3 (en) PROPIONIC ACID DERIVATIVES AND ASSOCIATED METHODS OF USE
EP4327880A3 (en) Solid state form of ribociclib succinate
WO2017177004A8 (en) Tertiary amides and method of use
TN2019000204A1 (en) Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same
MX2021003232A (es) Inhibidores de o-glicoproteina-2-acetamido-2-desoxi-3-d-glucopiran osidasa.
SG10201806809QA (en) 1-heterocyclyl isochromanyl compounds and analogs for treating cns disorders